Ticagrelor significantly reduced the incidence of the composite endpoint of cardiovascular death, myocardial infarction, and stroke (OR 0.83) compared to clopidogrel in patients with acute coronary syndrome.
Meta-Analysis (n=35,004)
Does ticagrelor reduce the composite endpoint of myocardial infarction, cardiovascular death, or stroke in patients with acute coronary syndrome compared to clopidogrel or prasugrel?
Ticagrelor effectively reduces the composite of cardiovascular death, myocardial infarction, and stroke in ACS patients compared to clopidogrel, but significantly increases the risk of dyspnea.
Odds Ratio: 0.83 (95% CI 0.77–0.9)
p-value: p=<0.00001
OBJECTIVE: In this study, a systematic evaluation was conducted to estimate the efficacy and safety of ticagrelor for treating acute coronary syndrome (ACS) in general ACS patients and a diabetes mellitus (DM) group. METHODS: A search of PubMed, Cochrane Central Register of Controlled Trials, Web of Science, CNKI databases was conducted to analyze relevant randomized controlled trails (RCTs) of ticagrelor treating ACS during 2007 to 2015. Article screening, quality accessing and data extracting was independently undertaken by two reviewers. A meta-analysis was performed to clarify the efficacy and safety of ticagrelor in general ACS patients, and a meta-regression analysis was taken to demonstrate the efficacy and safety of ticagrelor in DM patients compared with general ACS patients. RESULT: Twenty-two studies with 35004 participants were included. The meta-analysis result implicated that ticagrelor could: 1) reduce the incidence of the composite endpoint OR = 0.83, 95%CI (0.77, 0.90), P<0.00001 and the incidence of myocardial infarction OR = 0.81, 95%CI (0.74, 0.89), P = 0.0001; 2) not statistically reduce the incidence of cardiovascular death, the incidence of stroke and the incidence of bleeding events; 3) increase the incidence of dyspnea OR = 1.90, 95%CI (1.73, 2.08), P<0.00001 compared with clopidogrel. Meanwhile, compared with prasugrel, ticagrelor could 1) reduce the platelet reactivity of patients at maintenance dose MD = -44.59, 95%CI (-59.16, -30.02), P<0.00001; 2) not statistically reduce the incidence of cardiovascular death, the platelet reactivity of patients 6 hours or 8 hours after administration, or the incidence of bleeding events; 3) induce the incidence of dyspnea OR = 13.99, 95%CI (2.58, 75.92), P = 0.002. Furthermore, the result of meta-regression analysis implicated that there was a positive correlation between DM patients and the platelet reactivity of patients 6 hours and 8 hours after administration, but there was no obvious correlation between DM patients and general ACS patients in other endpoints. CONCLUSION: Ticagrelor could reduce the incidence of composite endpoint of cardiovascular death, myocardial infarction and stroke as well as platelet reactivity in DM patients with ACS, while not increasing the risk of bleeding. Because there are differences in platelet reactivity between DM patients and general ACS patients, we suggest that caution is needed when using ticagrelor in clinical applications.
Tan et al. (2017) conducted a meta-analysis in Acute coronary syndrome (n=35,004). Ticagrelor vs. Clopidogrel or Prasugrel was evaluated on Composite endpoint of myocardial infarction, cardiovascular death, or stroke (OR 0.83, 95% CI 0.77, 0.90, p=<0.00001). Ticagrelor significantly reduced the incidence of the composite endpoint of cardiovascular death, myocardial infarction, and stroke (OR 0.83) compared to clopidogrel in patients with acute coronary syndrome.